OGN

Business Context and Reporting Period

Organon & Co. (OGN) is a global healthcare company focused on women's health and general medicines, including biosimilars. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates six manufacturing facilities globally and sells products in over 140 countries. As of April 27, 2026, there were 262,600,862 shares of common stock outstanding.

Key Financial Metrics

Margins: Gross margin was approximately 53.6% in Q1 2026 compared to 55.6% in Q1 2025. The effective income tax rate was 31.4% in Q1 2026 versus 13.4% in Q1 2025.

Material Changes vs. Prior Period

• Revenue Decline: Worldwide sales decreased 4% to $1.46 billion, driven by a 13% decline in U.S. sales and a 7% decline in International sales (excluding foreign exchange). Key drivers included a 19% drop in Nexplanon sales due to delayed reinsertions and funding uncertainty, and a 46% drop in Singulair sales due to unfavorable guidelines and price reductions.
• Profitability Increase: Net income increased 68% to $146 million, primarily due to an $81 million net gain from the divestiture of the Jada System to Laborie Medical Technologies Corporation in January 2026.
• Restructuring Costs: Restructuring expenses decreased significantly to $31 million from $86 million in the prior year, reflecting a 3% headcount reduction in 2026 compared to a 6% reduction in 2025.
• Cash Flow: Operating cash flow improved to $225 million from $75 million, aided by active cash cycle management. Investing cash flow turned positive ($386 million) due to proceeds from the Jada divestiture.

Guidance, Outlook, Risks, and Unusual Items

Subsequent Event: Merger Agreement

On April 26, 2026, Organon entered into a definitive agreement to be acquired by Sun Pharmaceutical Industries Limited for $14.00 per share in cash. The transaction is expected to close in early 2027, subject to regulatory approvals and stockholder vote. If the merger fails, Organon faces a $120 million termination fee and potential liquidity challenges regarding its 2028 debt maturities.

Internal Control Weaknesses

The company disclosed material weaknesses in internal control over financial reporting that remained unremediated as of March 31, 2026. These stem from a failure to set an appropriate "tone at the top" regarding sales practices for Nexplanon and ineffective information communication controls. An SEC investigation into these sales practices is ongoing.

Other Unusual Items

• Jada Divestiture: The sale of the Jada System generated an $81 million gain and $433 million in cash proceeds, significantly impacting Q1 2026 results.
• Accounting Error: A $12 million error related to the fair value remeasurement of tax-related contingent consideration was identified and corrected in Q1 2026; management deemed it immaterial.
• Legal Proceedings: Significant product liability litigation continues regarding Fosamax and Nexplanon/Implanon, though recent Master Settlement Agreements in New Jersey and California are expected to resolve the majority of claims for confidential, non-material payments.

Investor Verification Checklist

• Merger Status: Monitor progress on regulatory approvals and stockholder voting for the Sun Pharma acquisition, including the risk of termination fees.
• Internal Controls: Track the remediation plan for material weaknesses in financial reporting and the outcome of the SEC investigation into Nexplanon sales practices.
• Debt Maturity: Assess the company's ability to refinance or repay approximately $3.5 billion in debt maturing in 2028 if the merger does not close.
• Product Performance: Verify the recovery trajectory of Nexplanon sales following the five-year label approval and the impact of generic competition on Singulair and other established brands.
• Divestiture Proceeds: Confirm the utilization of the $433 million cash proceeds from the Jada sale, specifically regarding mandatory debt prepayments.